Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
JANX Price/Volume Stats
| Current price | $48.96 | 52-week high | $65.60 |
| Prev. close | $49.01 | 52-week low | $7.79 |
| Day low | $47.61 | Volume | 391,400 |
| Day high | $49.34 | Avg. volume | 708,719 |
| 50-day MA | $50.06 | Dividend yield | N/A |
| 200-day MA | $43.51 | Market Cap | 2.57B |
JANX Stock Price Chart Interactive Chart >
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Price Returns
| 1-mo | -7.27% |
| 3-mo | 6.62% |
| 6-mo | 7.91% |
| 1-year | 437.43% |
| 3-year | 168.42% |
| 5-year | N/A |
| YTD | 356.29% |
| 2023 | -18.53% |
| 2022 | -33.25% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...